Back

Daré Bioscience adds U.S. patent 12,678,439 for DARE-HPV through 2039

Verifying
  • Daré Bioscience announced a new U.S. patent supporting development of DARE-HPV.
  • Approximately $10 million comes from ARPA-H, alongside a $2.0 million NIAID award.
  • DARE-HPV’s Phase 2 study involves approximately 100 women, with results expected in 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Daré Bioscience adds U.S. patent 12,678,439 for DARE-HPV through 2039 - CoinPost Terminal